Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

PrEP news

Show

From To
Sheena McCormack: helping to prepare the world for PrEP

As a clinician who has witnessed the devastating impact of the HIV/AIDS epidemic since the 1980s, Sheena McCormack is enthusiastic about her latest project, the UK Medical Research Council (MRC) PROUD study. As lead investigator, she has been investigating the effect of pre-exposure prophylaxis (PrEP) to protect against HIV infection in high-risk men who have sex with men (MSM). PROUD has shown that PrEP reduces new HIV infections by 86%.

Published
28 March 2015
From
The Lancet
Canada: PrEP use now could save considerable sums in the future

A Canadian paper that weighs the cost of using pre-exposure prophylaxis (PrEP) to prevent HIV infections against the lifetime total cost of one HIV infection finds that,

Published
20 March 2015
By
Gus Cairns
The State of HIV/AIDS Science and Treatment Literacy in the HIV/AIDS Workforce

This survey yields some disturbing findings. Overall, the HIV science and treatment knowledge of the HIV/AIDS workforce is far too low. In many cases, people working in HIV/AIDS appear to doubt the science behind breakthrough biomedical tools for HIV prevention, and far too many members of the workforce are not familiar with many of the bio-medical interventions that will play a critical role in ending the epidemic.

Published
18 March 2015
From
Black AIDS Institute
US: A Near-Failing Science Grade for the Non-Medical HIV Workforce

On average, the survey respondents answered just 63 percent of the questions correctly, including 76 percent of those covering basic knowledge and terminology, 56 percent of the HIV treatment questions, and 46 percent of those on the use of ARVs to prevent transmission of the virus. Only 19 percent of the respondents scored 80 percent or higher on the test.

Published
18 March 2015
From
AIDSMeds
When Might Generic Truvada Be Available for PrEP in the US?

Our best guess is that generic Truvada could be available in December 2017, initially produced by Teva, a major generic producer. Two other generic companies, Lupin Pharmaceuticals and Cipla may follow soon after creating competition that can really bring prices down.

Published
17 March 2015
From
Ethan The Blog
Dr. Robert Grant: What Does Ipergay Tell Us About PrEP and ‘Seasons of Risk’?

Much-anticipated efficacy results from a French study of intermittent PrEP were announced at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) at the end of February. Although PrEP experts do not have enough information from this relatively small study of men to advise or recommend intermittent PrEP use, Ipergay does add to clinical knowledge about one important issue: how to stop using PrEP if it’s no longer needed.

Published
13 March 2015
From
BETA
Schooling Primary Care Doctors About HIV and PrEP

Patients seeking drugs to prevent HIV infection may face resistance from primary care doctors who are not trained in HIV care. Some frustrated patients have launched personal educational campaigns to get the word out.

Published
10 March 2015
From
Healthline
Partners launch phase 2 safety study of a long-acting injectable to prevent HIV

PATH, in collaboration with the US National Institutes of Health (NIH) and the HIV Prevention Trials Network (HPTN), has launched a new study to test the safety and acceptability of a long-acting injectable formulation of the proven antiretroviral drug rilpivirine (TMC278) as a pre-exposure prophylaxis (PrEP) against HIV.

Published
06 March 2015
From
PATH
PrEP Access For HIV Prevention In Australia A Step Closer As Gilead Applies To TGA

US pharmaceutical giant Gilead Sciences has begun the application process to have Truvada approved for PrEP in Australia, removing one of the most significant hurdles currently preventing access to the HIV-prevention drug and opening the door to affordable access.

Published
03 March 2015
From
Star Observer
Levels of maraviroc in vaginal and rectal tissues may not be high enough for pre-exposure prophylaxis

Levels of the HIV entry inhibitor maraviroc (Celsentri/Selzentry) in vaginal and rectal tissues did not reach high enough levels with a single oral dose to confer protection

Published
02 March 2015
By
Liz Highleyman
← First12345...53Next →

Filter by country